Revenio Group Corporation’s financial reporting and Annual General Meeting in 2025

Revenio Group Corporation will publish the following financial reports in 2025:

• Financial Statements Bulletin for the year 2024 on Thursday, February 13, 2025
• Annual reporting package 2024 will be published during week 12 in 2025
• Interim report 1-3/2025 on Tuesday, April 29, 2025
• Half-year financial report 1-6/2025 on Thursday, August 7, 2025
• Interim report 1-9/2025 on Thursday, October 30, 2025

The financial statements bulletin, half-year report and interim reports will be published at approximately 9.00 am Finnish time on the above dates.

The Annual General Meeting is planned to be held on Thursday, April 10, 2025. The Board of Directors of the company will convene the meeting.

A shareholder, who wishes to include an item on the agenda of the Annual General Meeting, shall submit the request in writing to the company's Board of Directors by February 21, 2025. Such requests including the reasoning, or a resolution proposal can be submitted to the address: Revenio Group Corporation / Board of Directors, Äyritie 22, FI-01510 Vantaa, Finland.

For further information, please contact
Robin Pulkkinen, CFO, tel. +358 50 505 9932
[email protected]

Distribution
Nasdaq Helsinki
Financial Supervisory Authority (FIN-FSA)
Key media
www.reveniogroup.fi/en

Revenio Group in brief
Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and age-related macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand.

In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.